



TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Result of General Meeting

and

Total Voting Rights

Alderley Park, UK - 7 March 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that at the General Meeting held today at Mereside - No. 11 Lecture Theatre, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, all resolutions were duly passed.

Details of the proxy voting instructions lodged prior to the General Meeting for each Resolution are shown on the Company's website.

Total Voting Rights

The 1,620,315,527 New Ordinary Shares to be issued pursuant to the Fundraising are expected to be admitted to trading on AIM at 8 a.m. on 11 March 2025. Following this Second Admission, the total number of Ordinary Shares in issue will be 2,129,622,422, with no shares held in treasury. This is the figure that may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, terms used in this announcement have the meaning given to them in the £4.25m Placing & Subscription and Notice of GM announcement dated 19 February 2025.

Enquiries

TheraCryf plc

Dr Alastair Smith, Chair
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO

+44 (0)1625 315 090

enquiries@theracryf.com

Cavendish Capital Markets (NOMAD & Joint Broker)

Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

+44 (0)20 7220 0500

Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker

+44 (0)20 3657 0050

Vigo Consulting

Rozi Morris

+44 (0)20 7390 0231

theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalica SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.

For further information, please visit: www.theracryf.com.

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMUPUGUWUPAGPM